Replies to post #150608 on Biotech Values

[DewDiligence]

The late relapses you’re referring to occurred in the PILOT study, which tested ABT-450/r + ABT-072 (a non-nuke) + ribavirin; i.e. it had no NS5A inhibitor. The study we’re discussing today, called AVIATOR, tested ABT-450/r + ABT-267 (a newer non-nuke than ABT-072) + ABT-333 (NS5A) + ribavirin.

[DewDiligence]

ABT—I'd like to see a breakout of G1a vs G1b [in the AVIATOR study]

The breakdown was roughly 2/3 - 1/3. Also, only 30% of patients in the study had the beneficial CC variant of IL28B.